216 related articles for article (PubMed ID: 32059632)
1. Practical Considerations for the Use of Sodium-Glucose Co-Transporter 2 Inhibitors in Heart Failure.
Honigberg MC; Vardeny O; Vaduganathan M
Circ Heart Fail; 2020 Feb; 13(2):e006623. PubMed ID: 32059632
[No Abstract] [Full Text] [Related]
2. The Ethics of Conducting Clinical Trials With Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: Is Placebo Assignment Justified in Patients With Comorbid Diabetes Mellitus and Heart Failure?
Butler J; Anker SD
Circulation; 2017 Oct; 136(16):1459-1461. PubMed ID: 29038205
[No Abstract] [Full Text] [Related]
3. Sodium-glucose co-transporter 2 inhibitors for the prevention of heart failure in type 2 diabetes: A systematic review and meta-analysis.
Yamani N; Usman MS; Akhtar T; Fatima K; Asmi N; Khan MS
Eur J Prev Cardiol; 2020 Apr; 27(6):667-670. PubMed ID: 30966822
[No Abstract] [Full Text] [Related]
4. Resistance to Diuretics in Heart Failure: Any Role for Empagliflozin?
Katsiki N; Triposkiadis F
Curr Vasc Pharmacol; 2019; 17(4):421-424. PubMed ID: 30173648
[No Abstract] [Full Text] [Related]
5. Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus.
Berg DD; Wiviott SD; Scirica BM; Gurmu Y; Mosenzon O; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Johanson P; Johansson PA; Langkilde AM; Raz I; Braunwald E; Sabatine MS
Circulation; 2019 Nov; 140(19):1569-1577. PubMed ID: 31474116
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for Patients With Heart Failure in China: A New Pillar in Our Pockets, but at What Price?
Camilli M; Ballacci F; Giordano F; Minotti G
J Cardiovasc Pharmacol; 2024 Jan; 83(1):43-45. PubMed ID: 37815278
[No Abstract] [Full Text] [Related]
7. Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus.
Greene SJ; Butler J
Circulation; 2019 Jan; 139(2):152-154. PubMed ID: 30615507
[No Abstract] [Full Text] [Related]
8. Prescribing sodium-glucose co-transporter-2 inhibitors for type 2 diabetes in primary care: influence of renal function and heart failure diagnosis.
Hinton W; Feher MD; Munro N; Joy M; de Lusignan S
Cardiovasc Diabetol; 2021 Jun; 20(1):130. PubMed ID: 34183018
[TBL] [Abstract][Full Text] [Related]
9. Importance of sodium-glucose cotransporter 2 inhibitor use in diabetic patients with acute heart failure.
Kambara T; Shibata R; Osanai H; Nakashima Y; Asano H; Murohara T; Ajioka M
Ther Adv Cardiovasc Dis; 2019; 13():1753944719894509. PubMed ID: 31854243
[TBL] [Abstract][Full Text] [Related]
10. Sodium-glucose cotransporter-2 inhibitors in type 2 diabetes: a magic potion to reduce heart failure?
Pafili K; Papanas N
Expert Rev Clin Pharmacol; 2019 Aug; 12(8):693-695. PubMed ID: 31232616
[No Abstract] [Full Text] [Related]
11. Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study.
Kim YG; Han SJ; Kim DJ; Lee KW; Kim HJ
Cardiovasc Diabetol; 2018 Jun; 17(1):91. PubMed ID: 29935543
[TBL] [Abstract][Full Text] [Related]
12. Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus.
Figtree GA; Rådholm K; Barrett TD; Perkovic V; Mahaffey KW; de Zeeuw D; Fulcher G; Matthews DR; Shaw W; Neal B
Circulation; 2019 May; 139(22):2591-2593. PubMed ID: 30882240
[No Abstract] [Full Text] [Related]
13. Heart Failure and Diabetes: Perspective of a Dangerous Association.
Favaloro LE; Ratto RD; Musso C
Curr Hypertens Rev; 2021; 17(2):85-93. PubMed ID: 33823781
[TBL] [Abstract][Full Text] [Related]
14. Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure.
Liang B; Gu N
Cardiovasc Diabetol; 2022 May; 21(1):84. PubMed ID: 35624512
[TBL] [Abstract][Full Text] [Related]
15. Sodium-glucose co-transporter 2 inhibitors and heart failure-the present and the future.
Nana M; Morgan H; Bondugulapati LNR
Heart Fail Rev; 2021 Jul; 26(4):953-960. PubMed ID: 32020487
[TBL] [Abstract][Full Text] [Related]
16. Focused Updates: SGLT2 Inhibitors in Patients With Heart Failure and/or Chronic Kidney Disease.
Cheng JWM; Colucci V; Kalus JS; Spinler SA
Ann Pharmacother; 2021 Feb; 55(2):252-260. PubMed ID: 32536199
[TBL] [Abstract][Full Text] [Related]
17. Empagliflozin and Major Renal Outcomes in Heart Failure.
Packer M; Butler J; Zannad F; Pocock SJ; Filippatos G; Ferreira JP; Brueckmann M; Jamal W; Zeller C; Wanner C; Anker SD;
N Engl J Med; 2021 Oct; 385(16):1531-1533. PubMed ID: 34449179
[No Abstract] [Full Text] [Related]
18. Risk stratification tools for heart failure in the diabetes clinic.
Cannistraci R; Mazzetti S; Mortara A; Perseghin G; Ciardullo S
Nutr Metab Cardiovasc Dis; 2020 Jun; 30(7):1070-1079. PubMed ID: 32475628
[TBL] [Abstract][Full Text] [Related]
19. Diamonds in the Rough: The Incredible-but-True Story of Sodium Glucose Cotransporter 2 Inhibitors in Treatment of Heart Failure.
Kosiborod M
Circulation; 2021 Jan; 143(4):350-353. PubMed ID: 33493031
[No Abstract] [Full Text] [Related]
20. Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality.
Savarese G; Sattar N; Januzzi J; Verma S; Lund LH; Fitchett D; Zeller C; George JT; Brueckmann M; Ofstad AP; Inzucchi SE; Wanner C; Zinman B; Butler J
Circulation; 2019 Mar; 139(11):1458-1460. PubMed ID: 30855996
[No Abstract] [Full Text] [Related]
[Next] [New Search]
